Virostatics Doses First Patient In Phase IIa Trial Of VS411 For The Treatment Of HIV Infection
May 15th 2008Drug InformationClinical Trials
Virostatics, srl, a privately-held pharmaceutical company focused on the discovery and development of combination therapeutics in HIV/AIDS, virology, and other chronic diseases, announced it has initiated dosing of subjects in its five-arm, dose-ranging, proof of principle study VS411-C201: A randomized double-blind dose-finding multi-centre Phase IIa study with VS411 for HIV-1 infection.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
